The Effect of Menstrual Cycle Phase and Protein Dose on Muscle Protein Synthesis

NCT ID: NCT05178732

Last Updated: 2024-07-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-16

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Adaptation to resistance exercise requires maximal rates of muscle protein synthesis, which can be achieved with post-exercise ingestion of \~20g of protein. These recommendations are based on studies in males and responses in females may vary.

Muscle recovery is related to the ability to build new muscle protein from amino acids (muscle protein synthesis). This response is thought to be impacted in females by hormones that fluctuate across different phases of the menstrual cycle. However, the effect of menstrual cycle phase on muscle protein synthesis is not known.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Protein Synthesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Protein dose 1 and early

Group Type EXPERIMENTAL

Dose of protein

Intervention Type DIETARY_SUPPLEMENT

One of three protein doses provided

Menstrual cycle phase

Intervention Type OTHER

Different phase of the menstrual cycle

Protein dose 1 and late

Group Type EXPERIMENTAL

Dose of protein

Intervention Type DIETARY_SUPPLEMENT

One of three protein doses provided

Menstrual cycle phase

Intervention Type OTHER

Different phase of the menstrual cycle

Protein dose 2 and early

Group Type EXPERIMENTAL

Dose of protein

Intervention Type DIETARY_SUPPLEMENT

One of three protein doses provided

Menstrual cycle phase

Intervention Type OTHER

Different phase of the menstrual cycle

Protein dose 2 and late

Group Type EXPERIMENTAL

Dose of protein

Intervention Type DIETARY_SUPPLEMENT

One of three protein doses provided

Menstrual cycle phase

Intervention Type OTHER

Different phase of the menstrual cycle

Protein dose 3 and early

Group Type EXPERIMENTAL

Dose of protein

Intervention Type DIETARY_SUPPLEMENT

One of three protein doses provided

Menstrual cycle phase

Intervention Type OTHER

Different phase of the menstrual cycle

Protein dose 3 and late

Group Type EXPERIMENTAL

Dose of protein

Intervention Type DIETARY_SUPPLEMENT

One of three protein doses provided

Menstrual cycle phase

Intervention Type OTHER

Different phase of the menstrual cycle

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dose of protein

One of three protein doses provided

Intervention Type DIETARY_SUPPLEMENT

Menstrual cycle phase

Different phase of the menstrual cycle

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BMI between 18 and 30
* Recreationally active
* Regular menstrual cycle

Exclusion Criteria

* Smoking
* Metabolic disease
* Any motor disorder
* Use of over-the-counter pharmaceuticals, during the study.
* Pomegranate, milk or lidocaine allergy
* Taken contraceptives in the past 3 months
* Irregular menstrual cycle (less than 9 cycles per year and a length not between 21-35 days)
* Post-menopausal women
* Pregnancy and lactation
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

P.volve

UNKNOWN

Sponsor Role collaborator

University of Exeter

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Francis Stephens

Role: PRINCIPAL_INVESTIGATOR

University of Exeter

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Exeter

Exeter, Devon, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

21-10-20-B-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.